Compare iShares MSCI France ETF (EWQ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs ResMed Inc. — how do they compare? iShares MSCI France ETF trades at $41.52 (market cap $330.91M), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 96.4× iShares MSCI France ETF's market cap, and ResMed Inc. pays a 1.16% dividend while iShares MSCI France ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 55 Days and ResMed Inc. for 51 Days on average.
| EWQ | RMD | |
|---|---|---|
Market Cap | $330.91M | $31.89B |
Volume | 556,654 | 618,314 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $277.88 |
52-Week Low | $41.32 | $182.82 |
Typical Hold Time | 55 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is trading at $41.52 with a slight 0.44% daily gain, though technical indicators show a bearish bias with moving averages signaling strong selling pressure. The stock faces mixed sentiment with oscillators suggesting potential oversold conditions while European market uncertainties create headwinds. Recent news highlights ECB rate hikes and energy-driven inflation concerns affecting European equities.
The stock's outlook remains cautious with technical weakness offset by potential oversold bounce opportunities. Key risks include European economic sentiment deterioration and persistent inflation pressures, while the absence of fundamental data requires careful monitoring of upcoming financial disclosures for valuation clarity.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
